ライフサイエンスコーパス: immunodeficiency

1 ons in several NF-kappaB pathway genes cause immunodeficiency.

2 f these cells is considered a major cause of immunodeficiency.

3 te and safe use of vaccines in patients with immunodeficiency.

4 Deficiency of either subunit leads to severe immunodeficiency.

5 cal event/year, demonstrating their profound immunodeficiency.

6 allelic LRBA mutations cause common variable immunodeficiency-8; however, NDM has not been confirmed

7 ncies (10 [43.5%] vs 4 [12.9%]; P = .02) and immunodeficiencies (9 [39.1%] vs 3 [9.7%]; P = .02).

8 Immunodeficiency and (chronic/oncogenic) viral infection

9 vator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17 cel

10 ells that likely contribute to the patients' immunodeficiency and autoimmunity.

11 CD70 deficiency is a novel cause of combined immunodeficiency and EBV-associated diseases, reminiscen

12 is a novel molecular defect causative in TH1 immunodeficiency and genomic instability in patients wit

13 with a multisystem disorder characterized by immunodeficiency and neurological symptoms.

14 multisystem disorder with failure to thrive, immunodeficiency and neurological symptoms.

15 with progressive bone marrow failure (BMF), immunodeficiency, and developmental aberrations.

16 formation could represent a cause of NK cell immunodeficiency, and interrupting STAT5 tetramer format

17 ficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatmen

18 ersus-host disease (GVHD) and posttransplant immunodeficiency are frequently related complications of

19 and multiple diseases where autoimmunity and immunodeficiency are major components.

20 menn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity and caused

21 n (WASp) expression or activity, manifest in immunodeficiency, autoimmunity, genomic instability, and

22 Severe combined immunodeficiency can be caused by loss-of-function mutat

23 Identifying how natural hosts avoid immunodeficiency can elucidate key mechanisms of pathoge

24 tokinesis 8 (DOCK8) deficiency is a combined immunodeficiency caused by autosomal recessive loss-of-f

25 ts with anhidrotic ectodermal dysplasia with immunodeficiency caused by mutations in the nuclear fact

26 deling protein Lsh/HELLS can cause the human Immunodeficiency, Centromere instability and Facial anom

27 e DNMT3B cause majority of the rare disorder Immunodeficiency, Centromere instability and Facial anom

28 emophagocytic lymphohistiocytosis, a primary immunodeficiency characterized by impaired lytic granule

29 eceptor subunit give rise to severe combined immunodeficiency characterized by lack of T and natural

30 n reported in the WHIM Syndrome (WS), a rare immunodeficiency characterized by lymphopenia.

31 Combined immunodeficiency (CID) is a T-cell defect frequently pre

32 The various immunodeficiency conditions identified thus far in assoc

33 Common variable immunodeficiency (CVID) is a heterogeneous syndrome char

34 Most patients with common variable immunodeficiency (CVID) present with severely reduced sw

35 ated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations

36 urgent need for the establishment of primary immunodeficiency disease registries, stem cell transplan

37 incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United

38 Analyses of other genes mutated in primary immunodeficiency diseases (PIDs) where reversions have b

39 rstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune s

40 Physicians caring for patients with primary immunodeficiency diseases were identified through the Je

41 ment whose improper regulation causes severe immunodeficiency diseases.

42 mergence of many autosomal recessive primary immunodeficiency diseases.

43 lignancies, inborn errors of metabolism, and immunodeficiency disorders, yet complications such as gr

44 tients with OS significantly ameliorates the immunodeficiency, even in an inflammatory environment.

45 rtain manifestations of HIV disease, such as immunodeficiency events in patients with greater than 50

46 In contrast to primary immunodeficiencies, fundamental immunodeficiency is not

47 ledge of immune function and appreciation of immunodeficiency has developed, researchers have used va

48 transplantation and gene therapy for primary immunodeficiency have had relative success; the use of a

49 tions that cause Mendelian monogenic primary immunodeficiency have not previously been identified.

50 ucible T cell kinase (Itk) results in T cell immunodeficiency in mice and humans.

51 t to primary immunodeficiencies, fundamental immunodeficiency is not rare but nearly universal.

52 "Fundamental immunodeficiency" is the inability of the encoded immune

53 n a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome (OS).

54 terozygous GATA2 mutation is associated with immunodeficiency, lymphedema, and myelodysplastic syndro

55 clude that IFIH1 deficiency causes a primary immunodeficiency manifested in extreme susceptibility to

56 or in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenografts.

57 anted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapitulated clinical

58 nd LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

59 ed tumor xenograft growth in severe combined immunodeficiency mice.

60 ive, and mixed tumor-bearing severe combined immunodeficiency mice.

61 thetic LAT gene bearing this severe combined immunodeficiency mutation.

62 the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Imm

63 itors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulted in the formati

64 eam transcription factors that cause primary immunodeficiency or autoimmune conditions.

65 l age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent.

66 Primary immunodeficiencies (PIDs) are inherited diseases associa

67 s used as a therapeutic approach for primary immunodeficiencies (PIDs).

68 e most extreme cases being Mendelian primary immunodeficiencies (PIDs).

69 efficacy, HIV co-infection and the resulting immunodeficiency prompts safety concerns about their use

70 Severe combined immunodeficiency (SCID) is characterized by severely imp

71 ) is enrolling children with severe combined immunodeficiency (SCID) to a prospective natural history

72 Severe combined immunodeficiency (SCID) with a complete absence of T cel

73 proportion of patients with severe combined immunodeficiency (SCID).

74 tion (HSCT) in patients with severe combined immunodeficiency (SCID).

75 -chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

76 d genes newly reported to be associated with immunodeficiency, such as linker of activation of T cell

77 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) event

78 degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

79 8-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.79).

80 a, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant results.

81 ort two sibling pairs with syndromic primary immunodeficiencies that exceptionally presented with a p

82 form of anhidrotic ectodermal dysplasia with immunodeficiency that is distinct from previously report

83 Surprisingly, bovine immunodeficiency virus (BIV) Vif, but not HIV-1 Vif, int

84 ission pathways for three subtypes of feline immunodeficiency virus (FIVPle ) in African lions (Panth

85 (HPV) types among women infected with human immunodeficiency virus (HIV) (WHIV) are needed to inform

86 /E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, wani

87 are known to be moderately potent antihuman immunodeficiency virus (HIV) agents, while being complet

88 sexual networks in the epidemiology of human immunodeficiency virus (HIV) among black men who have se

89 are quality and access for people with human immunodeficiency virus (HIV) and acquired immune deficie

90 T availability, the burden of advanced human immunodeficiency virus (HIV) and associated opportunisti

91 ogic control in children infected with human immunodeficiency virus (HIV) and exposed to nevirapine (

92 udinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)

93 Human immunodeficiency virus (HIV) and simian immunodeficiency

94 Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C

95 Human immunodeficiency virus (HIV) antibodies are generated an

96 ected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver d

97 nsuring that 90% of people living with human immunodeficiency virus (HIV) are diagnosed, 90% start tr

98 of children infected perinatally with human immunodeficiency virus (HIV) are surviving to adolescenc

99 cities, had negative test results for human immunodeficiency virus (HIV) but were at high risk for a

100 ) viral suppression among persons with human immunodeficiency virus (HIV) by 2020.

101 Perinatal transmission of human immunodeficiency virus (HIV) can be reduced through serv

102 n similar in patients with and without human immunodeficiency virus (HIV) coinfection; however, in th

103 n has always been an important part of human immunodeficiency virus (HIV) disease and its experience

104 y is important for control of maternal human immunodeficiency virus (HIV) disease and the prevention

105 ngly predicts mortality during treated human immunodeficiency virus (HIV) disease in Ugandans as comp

106 o assess the role of thymic failure in human immunodeficiency virus (HIV) disease progression.

107 During human immunodeficiency virus (HIV) disease, chronic immune act

108 ich represents a target for novel anti-human immunodeficiency virus (HIV) drug development.IMPORTANCE

109 iving factor behind the development of human immunodeficiency virus (HIV) drug resistance (HIVDR) in

110 The emergence and spread of human immunodeficiency virus (HIV) drug resistance from antire

111 In Western countries emergence of human immunodeficiency virus (HIV) drug resistance has tremend

112 High-quality, simplified, and low-cost human immunodeficiency virus (HIV) drug resistance tests that

113 associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to

114 stribution of cell subsets that harbor human immunodeficiency virus (HIV) during antiretroviral thera

115 he well-documented viral archeology of human immunodeficiency virus (HIV) emergence following human e

116 The human immunodeficiency virus (HIV) epidemic in Ukraine has bee

117 A long-standing question of human immunodeficiency virus (HIV) genetic variation and evolu

118 Human immunodeficiency virus (HIV) has a number of circulating

119 lizing antibodies directed against the human immunodeficiency virus (HIV) has received considerable a

120 other-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) have been scaled up in many

121 Black women bear the highest burden of human immunodeficiency virus (HIV) infection among US women.

122 Bone loss occurs in human immunodeficiency virus (HIV) infection but paradoxically

123 ed countries has changed the course of Human Immunodeficiency Virus (HIV) infection from an almost un

124 on of coronary heart disease (CHD) and human immunodeficiency virus (HIV) infection has been well rec

125 Human immunodeficiency virus (HIV) infection is a recognized r

126 tential to induce hepatic steatosis in human immunodeficiency virus (HIV) infection need to be identi

127 02 asymptomatic Air Force members with human immunodeficiency virus (HIV) infection revealed 19 (18.6

128 s in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide.

129 EP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compens

130 ause of meningitis in individuals with human immunodeficiency virus (HIV) infection, resulting in dea

131 n Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of deat

132 mpounds the negative health effects of human immunodeficiency virus (HIV) infection.

133 g active tuberculosis in patients with human immunodeficiency virus (HIV) infection.

134 ive strategy to prevent acquisition of human immunodeficiency virus (HIV) infection.

135 ajor complication for individuals with human immunodeficiency virus (HIV) infection.

136 nuary 2015, an outbreak of undiagnosed human immunodeficiency virus (HIV) infections among persons wh

137 sfunction observed in simian (SIV) and human immunodeficiency virus (HIV) infections.

138 thorough understanding of the role of human immunodeficiency virus (HIV) intrahost evolution in AIDS

139 quality, and proactively using data of human immunodeficiency virus (HIV) load testing are pivotal to

140 combination strategy for prevention of human immunodeficiency virus (HIV) on the incidence of HIV inf

141 s the epidemiological epicenter of the human immunodeficiency virus (HIV) pandemic, the Democratic Re

142 2 polymorphism on the adaptive WMT, in human immunodeficiency virus (HIV) participants compared to se

143 care (POC) diagnostic technologies for human immunodeficiency virus (HIV) patients in resource-limite

144 ,446 respondents to a tuberculosis and human immunodeficiency virus (HIV) prevalence survey that was

145 Human immunodeficiency virus (HIV) remains a significant sourc

146 Human immunodeficiency virus (HIV) reverse transcriptase (RT)-

147 rding the time course and magnitude of human immunodeficiency virus (HIV) RNA decay in semen.

148 ivation is suspected to modulate local human immunodeficiency virus (HIV) RNA levels and the risk of

149 persists despite suppression of plasma human immunodeficiency virus (HIV) RNA.

150 eutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) show great promise in HIV p

151 , moderate malnutrition, or an unknown human immunodeficiency virus (HIV) status in an HIV-endemic se

152 prophylaxis programs involve frequent human immunodeficiency virus (HIV) testing.

153 HR-HPV) is higher in women living with human immunodeficiency virus (HIV) than in the general populat

154 Persons with human immunodeficiency virus (HIV) that is treated with antire

155 l inflammation is a key determinant of human immunodeficiency virus (HIV) transmission, and may incre

156 The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integ

157 Human immunodeficiency virus (HIV) type 1 uses the CD4 molecul

158 An important goal of human immunodeficiency virus (HIV) vaccine design is identific

159 e formed by the capsid protein (CA) of human immunodeficiency virus (HIV) was self-assembled as a mon

160 Individuals infected with human immunodeficiency virus (HIV) who have previously had syp

161 he majority of individuals living with human immunodeficiency virus (HIV) worldwide.

162 es (NCDs) among individuals aging with human immunodeficiency virus (HIV), but few studies have descr

163 prevalent among persons infected with human immunodeficiency virus (HIV), but its long-term effects

164 ort that the tetraspanin CD81 enhances human immunodeficiency virus (HIV)-1 reverse transcription in

165 predict the preventative efficacy of a human immunodeficiency virus (HIV)-1 vaccine.

166 may lead to improved understanding of human immunodeficiency virus (HIV)-associated cardiovascular d

167 g hospitalized patients diagnosed with human immunodeficiency virus (HIV)-associated tuberculosis rem

168 Human immunodeficiency virus (HIV)-exposed infants are disprop

169 idely used in malaria-endemic areas in human immunodeficiency virus (HIV)-infected children and HIV-u

170 The incidence of clinical events in human immunodeficiency virus (HIV)-infected HCV-seropositive a

171 Human immunodeficiency virus (HIV)-infected individuals are at

172 Our data-driven model tracked human immunodeficiency virus (HIV)-infected individuals for 10

173 ral population, but their frequency in human immunodeficiency virus (HIV)-infected individuals is unk

174 nuation increases malaria incidence in human immunodeficiency virus (HIV)-infected individuals.

175 Depression affects up to 30% of human immunodeficiency virus (HIV)-infected individuals.

176 Disease progression is rapid in human immunodeficiency virus (HIV)-infected infants.

177 ma (KS), one of the leading cancers in human immunodeficiency virus (HIV)-infected patients in Zambia

178 on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and

179 Selected human immunodeficiency virus (HIV)-infected patients with end

180 Quantify proportion of human immunodeficiency virus (HIV)-infected patients with spec

181 ty-recruited prospective cohort of 961 human immunodeficiency virus (HIV)-infected people who inject

182 nes recommend that all sexually active human immunodeficiency virus (HIV)-infected persons be tested

183 rventions for prevention of malaria in human immunodeficiency virus (HIV)-infected pregnant women in

184 We characterized patterns of TDR among human immunodeficiency virus (HIV)-infected PWUD, and assessed

185 The numbers of human immunodeficiency virus (HIV)-infected women initiating a

186 Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infected women virologicall

187 Longitudinal data were analyzed from human immunodeficiency virus (HIV)-infected women who became p

188 Most human immunodeficiency virus (HIV)-infected youths are unaware

189 Among 601 human immunodeficiency virus (HIV)-negative tested controls, 3

190 d antiretroviral (ARV) treatment among human immunodeficiency virus (HIV)-positive men who have sex w

191 compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before ant

192 With an increasing number of human immunodeficiency virus (HIV)-positive persons seeking or

193 arneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in South and

194 nic Study of Atherosclerosis (MESA), a Human Immunodeficiency Virus (HIV)-uninfected cohort, which us

195 LTA4H genotype predicted survival of human immunodeficiency virus (HIV)-uninfected patients, with T

196 y in individuals who are infected with human immunodeficiency virus (HIV).

197 DS (UNAIDS) issued treatment goals for human immunodeficiency virus (HIV).

198 wn status, 38 (59%) were infected with human immunodeficiency virus (HIV).

199 ing a vaccine and novel treatments for human immunodeficiency virus (HIV).

200 g for the causative agent of AIDS, the human immunodeficiency virus (HIV).

201 e gaps remain about how the Ryan White human immunodeficiency virus (HIV)/AIDS Program (RW) contribut

202 R) events and mortality in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coi

203 ccessory proteins encoded by different human immunodeficiency virus (HIV)/simian immunodeficiency vir

204 ginal practices may be associated with human immunodeficiency virus (HIV-1) infection risk; however,

205 of morbidity among persons living with human immunodeficiency virus (HIV; PLWH).

206 morbidity and mortality in people with human immunodeficiency virus (PWHIV) on effective antiretrovir

207 istration of bNAbs in a macaque simian/human immunodeficiency virus (SHIV) model is associated with v

208 s in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterall

209 from pigtailed macaques infected with simian immunodeficiency virus (SIV) carrying HIV-1 reverse tran

210 immunodeficiency virus type 1 (HIV-1)/simian immunodeficiency virus (SIV) envelope spike (Env) mediat

211 y, we found that protection following simian immunodeficiency virus (SIV) exposure correlated with re

212 ORTANCE Rhesus macaque infection with simian immunodeficiency virus (SIV) has served as an important

213 ubtype C isolate was similar, while a simian immunodeficiency virus (SIV) isolate showed significant

214 nt human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) lentiviruses.

215 ocyte-depleted macaques infected with simian immunodeficiency virus (SIV) provide an increasingly uti

216 uman immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication in human cells

217 SM) are well-studied natural hosts of simian immunodeficiency virus (SIV) that do not progress to AID

218 mergence following human exposures to simian immunodeficiency virus (SIV), an understanding of proces

219 oteins of primate lentiviruses HIV-1, simian immunodeficiency virus (SIV), and BIV all form ubiquitin

220 idated in archival brain tissues from Simian Immunodeficiency Virus (SIV)-infected and uninfected rhe

221 Here, we show a population of simian immunodeficiency virus (SIV)-specific CD8 T cells expres

222 9, herpes simplex virus (HSV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus

223 49 [12.5] years, 31 [47%] of whom were human immunodeficiency virus [HIV]+) were analyzed.

224 is B surface antigen (HBsAg) positive, human immunodeficiency virus and hepatitis D virus-negative pa

225 ients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively samp

226 t from prototypic SIV encephalitis and human immunodeficiency virus encephalitis were identified.

227 sult of cross-species transmission of simian immunodeficiency virus from chimpanzees (SIVcpz).

228 iosis (CD40 ligand deficiency [n = 1], human immunodeficiency virus infection [n = 4]).

229 ns wearers (P = 0.21) or patients with human immunodeficiency virus infection or AIDS (P = 0.60).

230 Human immunodeficiency virus infection was independently assoc

231 Human immunodeficiency virus infection.

232 and obesity) and major infections like human immunodeficiency virus infection.

233 ation and inhibited wild-type SIVmac (simian immunodeficiency virus of macaques) infection of myeloid

234 of M41L + L210W + T215rev showed full human immunodeficiency virus RNA suppression while receiving a

235 emographics, clinical characteristics, human immunodeficiency virus status, and period of treatment.

236 le, low body mass index (<18.5 kg/m2), human immunodeficiency virus status, and study site, participa

237 sociodemographics, substance use, and human immunodeficiency virus status.

238 and reactive arthritis and facilitates human immunodeficiency virus transmission in men is weak, alth

239 rus type 2 (HSV-2; herpes) exacerbates human immunodeficiency virus type 1 (HIV) by unclear mechanism

240 essive T cell depletion during chronic human immunodeficiency virus type 1 (HIV) infection is a key m

241 Immune control of human immunodeficiency virus type 1 (HIV) infection is typical

242 shown to be preferentially targeted by human immunodeficiency virus type 1 (HIV-1) and are implicated

243 usive for important pathogens, such as human immunodeficiency virus type 1 (HIV-1) and herpesviruses,

244 er genes delivered by vectors based on human immunodeficiency virus type 1 (HIV-1) and Mason-Pfizer m

245 Although the human immunodeficiency virus type 1 (HIV-1) CA carboxy-termina

246 The human immunodeficiency virus type 1 (HIV-1) capsid protein is

247 Human immunodeficiency virus type 1 (HIV-1) drug resistance ge

248 Human immunodeficiency virus type 1 (HIV-1) entry into cells i

249 een the gp120 and gp41 subunits of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprot

250 tained in a quiescent state.IMPORTANCE Human immunodeficiency virus type 1 (HIV-1) establishes a pers

251 glycoprotein (Env) trimers of various human immunodeficiency virus type 1 (HIV-1) genotypes are bein

252 The hydrophobic groove of the human immunodeficiency virus type 1 (HIV-1) gp41 NHR trimer ha

253 ponents of vaccine-induced immunity to human immunodeficiency virus type 1 (HIV-1) in humans and SIV

254 ible tuberculosis in a setting of high human immunodeficiency virus type 1 (HIV-1) infection and tube

255 t proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection despite

256 Human immunodeficiency virus type 1 (HIV-1) infection is highl

257 infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection.

258 A hallmark of retroviruses such as human immunodeficiency virus type 1 (HIV-1) is reverse transcr

259 Human immunodeficiency virus type 1 (HIV-1) is the result of c

260 GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibit

261 The envelope glycoproteins (Envs) from human immunodeficiency virus type 1 (HIV-1) mediate viral entr

262 Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside reve

263 Human immunodeficiency virus type 1 (HIV-1) persists in latent

264 infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical

265 Full-length human immunodeficiency virus type 1 (HIV-1) RNA serves as the

266 us 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.

267 tency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in v

268 n are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1) vaccine developmen

269 with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)-infected (and 116

270 ith an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific immunity

271 which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1).

272 The human immunodeficiency virus type 1 (HIV-1)/simian immunodefic

273 Human immunodeficiency virus type-1 (HIV-1)-associated neuroco

274 s by DeltasigH was not reactivated by simian immunodeficiency virus, despite high viral levels and ma

275 extremities (ie, neuropathy related to human immunodeficiency virus, diabetes, or Fabry disease) can

276 both starting vaccination with single-cycle immunodeficiency virus, followed by two mucosal boosts w

277 g rubella, congenital cytomegalovirus, human immunodeficiency virus, hepatitis B virus, and neonatal

278 za virus, respiratory syncytial virus, human immunodeficiency virus, human T cell leukemia virus, hum

279 Human immunodeficiency virus-1 (HIV) targets the monocyte/macr

280 Human immunodeficiency virus-1 (HIV-1) infection currently req

281 Human immunodeficiency virus-infected individuals on cART (pre

282 onal cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T

283 eral flow assay (LF-LAM) results among human immunodeficiency virus-infected patients with disseminat

284 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy

285 ubella, cytomegalovirus, syphilis, and human immunodeficiency virus.

286 including an association with risk for human immunodeficiency virus.

287 of which may be linked to response to simian immunodeficiency virus.

288 >/=40 years, white, and infected with human immunodeficiency virus.

289 ses such as tuberculosis, malaria, and human immunodeficiency virus/acquired immunodeficiency syndrom

290 Patients with human immunodeficiency virus/AIDS-associated cryptococcal meni

291 We treated 6 human immunodeficiency virus/HCV coinfected kidney transplant

292 e infected rhesus macaques with simian-human immunodeficiency viruses (SHIV) and followed the dynamic

293 T-cell differentiation in defined monogenic immunodeficiencies, we sought to determine the profile o

294 Selected primary immunodeficiencies were chosen, the genetic defects of w

295 otype resembling early-onset common variable immunodeficiency, while extra-immunological characterist

296 naging the risks of individuals with primary immunodeficiencies who can excrete vaccine-derived polio

297 nked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compa

298 ould be considered in patients with combined immunodeficiency with T-cell abnormalities.

299 novel hairless strains exhibiting comparable immunodeficiency would be beneficial.

300 X-linked severe combined immunodeficiency (X-SCID) is an immune disorder caused b